Pamela Marrone - Mar 24, 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC (MBII)

Role
Director
Signature
/s/ Linda V. Moore, as attorney-in-fact
Stock symbol
MBII
Transactions as of
Mar 24, 2022
Transactions value $
-$9,228
Form type
4
Date filed
3/28/2022, 05:40 PM
Previous filing
Jan 18, 2022
Next filing
May 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBII Common Stock Options Exercise $16K +20K +0.9% $0.80 2.24M Mar 24, 2022 Direct
transaction MBII Common Stock Sale -$25.2K -22.7K -1.01% $1.11 2.22M Mar 24, 2022 Direct F1, F2
holding MBII Common Stock 6.44K Mar 24, 2022 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBII Stock Option (Right to buy) Options Exercise $0 -20K -46.17% $0.00 23.3K Mar 24, 2022 Common Stock 20K $0.80 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Ownership is held by Florence H. Marrone TOD Pamela G. Marrone.
F4 The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months.